RECRUITINGOBSERVATIONAL
DAratumumab and REvlimid REfractory MM
Salvage Regimens in Multiple Myeloma Patients Double Refractory to Lenalidomide and MoAbs: Evidence From Real World Experience
About This Trial
Retrospective and prospective multicenter observational study on patients with relapsed and refractory multiple myeloma after anti-CD38 MoAb therapy and IMIDS treated with onlabel regimens.
Who May Be Eligible (Plain English)
Who May Qualify:
Phase I
- Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme
- Patients aged ≥ 18 years
- Patients able to understand and voluntarily sign an willing to sign a consent form and be willing to consent to the review of clinical data
Phase II
- Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes
- Patients aged ≥ 18 years
- Patients able to understand and voluntarily sign an willing to sign a consent form and be willing to consent to the review of clinical data
Who Should NOT Join This Trial:
- Patients not willing to consent to review of clinical data
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
Phase I
* Patients with RRMM after therapy with anti-CD38 MoAb plus IMIDS started on therapy with PVD scheme
* Patients aged ≥ 18 years
* Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data
Phase II
* Patients with RRMM after first-line therapy with anti-CD38 MoAb plus IMIDS started on therapy with on-label schemes
* Patients aged ≥ 18 years
* Patients able to understand and voluntarily sign an informed consent and be willing to consent to the review of clinical data
Exclusion Criteria:
* Patients not willing to consent to review of clinical data
Locations (1)
Irccs San Matteo Pavia
Pavia, PV, Italy